Prevention of atherosclerosis by interference with the vascular nitric oxide system

Current Pharmaceutical Design

Volumn 15, Issue 27, 2009, Pages 3133-3145

  Li, Huige ^a   Förstermann, Ulrich ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Endothelial dysfunction; eNOs uncoupling; Nitric oxide; Tetrahydrobiopterin

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BETULIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; FOLIC ACID; GLYCERYL TRINITRATE; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; IRBESARTAN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; MIDOSTAURIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; PENTAERYTHRITYL TETRANITRATE; PROTEIN KINASE C INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEPIAPTERIN; TETRAHYDROBIOPTERIN; URSOLIC ACID; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SMOKING; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; HUMANS; HYPOLIPIDEMIC AGENTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 70449431340     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789058002     Document Type: Review

References (187)

1. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-1131
2. Liu VW, Huang PL. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 2008; 77: 19-29.
3. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190: 244-254 (Pubitemid 30141371)
4. Li H, Wallerath T, Forstermann U. Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide 2002; 7: 132-147 (Pubitemid 35177005)
5. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 998-1005. (Pubitemid 38737823)
6. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 445-450 (Pubitemid 38326136)
7. d'Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC, et al. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 1017-1022 (Pubitemid 34168662)
8. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-2157 (Pubitemid 27500136)
9. Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002; 7: 149-164 (Pubitemid 35346221)
10. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897-905. (Pubitemid 29152636)
11. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-2037
12. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146 (Pubitemid 29120084)
13. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1994; 14: 753-759 (Pubitemid 124004497)
14. Holm P, Korsgaard N, Shalmi M, Andersen HL, Hougaard P, Skouby SO, et al. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J Clin Invest 1997; 100: 821-828 (Pubitemid 27371700)
15. Kauser K, da Cunha V, Fitch R, Mallari C, Rubanyi GM. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol 2000; 278: H1679-85. (Pubitemid 30395582)
16. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol 1994; 14: 133-140 (Pubitemid 24028177)
17. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353
18. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation 1999; 99: 2979-2982 (Pubitemid 29270425)
19. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997; 17: 2479-2488 (Pubitemid 28015984)
20. Schwarz PM, Kleinert H, Forstermann U. Potential functional significance of brain-type and muscle-type nitric oxide synthase I expressed in adventitia and media of rat aorta. Arterioscler Thromb Vasc Biol 1999; 19: 2584-2590 (Pubitemid 29536031)
21. Kuhlencordt PJ, Hotten S, Schodel J, Rutzel S, Hu K, Widder J, et al. Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol 2006; 26: 1539-1544 (Pubitemid 44288980)
22. Lowenstein CJ. Beneficial effects of neuronal nitric oxide synthase in atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 1417-1418 (Pubitemid 44288962)
23. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001; 103: 3099-3104 (Pubitemid 32587858)
24. Upmacis RK, Crabtree MJ, Deeb RS, Shen H, Lane PB, Benguigui LE, et al. Profound biopterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. Am J Physiol Heart Circ Physiol 2007; 293: H2878-87. (Pubitemid 350106511)
25. Hodgin JB, Knowles JW, Kim HS, Smithies O, Maeda N. Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice. J Clin Invest 2002; 109: 541-548 (Pubitemid 34171786)
26. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 2000; 105: 451-458 (Pubitemid 30127245)
27. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001; 104: 448-454 (Pubitemid 32678276)
28. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 2001; 104: 2391-2394 (Pubitemid 33108369)
29. Shi W, Wang X, Shih DM, Laubach VE, Navab M, Lusis AJ. Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation 2002; 105: 2078-2082 (Pubitemid 34465271)
30. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002; 110: 331-340 (Pubitemid 34847965)
31. van Haperen R, de Waard M, van Deel E, Mees B, Kutryk M, van Aken T, et al. Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J Biol Chem 2002; 277: 48803-48807 (Pubitemid 35470847)
32. Forstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 2006; 387: 1521-1533 (Pubitemid 44837576)
33. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-1714 (Pubitemid 43754233)
34. Sullivan JC, Pollock JS. Coupled and uncoupled NOS: separate but equal? Uncoupled NOS in endothelial cells is a critical pathway for intracellular signaling. Circ Res 2006; 98: 717-719
35. Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, et al. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res 2005; 97: 864-871 (Pubitemid 41317851)
36. Bevers LM, Braam B, Post JA, van Zonneveld AJ, Rabelink TJ, Koomans HA, et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 2006; 47: 87-94. (Pubitemid 43177820)
37. Pritchard KA, Jr., Ackerman AW, Gross ER, Stepp DW, Shi Y, Fontana JT, et al. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 17621-17624 (Pubitemid 37411311)
38. Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard KA, Jr., et al. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem 2003; 278: 44719-44726 (Pubitemid 37377229)
39. Gharavi NM, Baker NA, Mouillesseaux KP, Yeung W, Honda HM, Hsieh X, et al. Role of endothelial nitric oxide synthase in the regulation of SREBP activation by oxidized phospholipids. Circ Res 2006; 98: 768-776 (Pubitemid 43755260)
40. Fleming I, Mohamed A, Galle J, Turchanowa L, Brandes RP, Fisslthaler B, et al. Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCalpha. Cardiovasc Res 2005; 65: 897-906. (Pubitemid 40249734)
41. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002; 109: 817-826 (Pubitemid 34263158)
42. Sud N, Wells SM, Sharma S, Wiseman DA, Wilham J, Black SM. Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction. Am J Physiol Cell Physiol 2008; 294: C1407-18.
43. Gao YT, Roman LJ, Martasek P, Panda SP, Ishimura Y, Masters BS. Oxygen metabolism by endothelial nitric-oxide synthase. J Biol Chem 2007; 282: 28557-28565 (Pubitemid 47606027)
44. Wei CC, Wang ZQ, Tejero J, Yang YP, Hemann C, Hille R, et al. Catalytic reduction of a tetrahydrobiopterin radical within nitric-oxide synthase. J Biol Chem 2008; 283: 11734-11742
45. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998; 273: 25804-25808 (Pubitemid 28475808)
46. Vasquez-Vivar J, Martasek P, Whitsett J, Joseph J, Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem J 2002; 362: 733-739 (Pubitemid 34242326)
47. Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res 2003; 37: 121-127 (Pubitemid 36124338)
48. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes 1999; 48: 2437-2445 (Pubitemid 30395437)
49. Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol 2002; 22: 1655-1661
50. Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol Heart Circ Physiol 2008; 294: H1530-40.
51. Pritchard KA, Jr., Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77: 510-518
52. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103: 1282-1288 (Pubitemid 32221353)
53. Li H, Witte K, August M, Brausch I, Godtel-Armbrust U, Habermeier A, et al. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 2006; 47: 2536-2544 (Pubitemid 43866358)
54. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 1999; 33: 1353-1358 (Pubitemid 29282653)
55. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90: E58-65.
56. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-1209 (Pubitemid 36519937)
57. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: E14-22.
58. Munzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000; 86: E7-12.
59. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-46 (Pubitemid 27058292)
60. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000; 43: 1435-1438 (Pubitemid 30816014)
61. Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002; 15: 326-332 (Pubitemid 34408972)
62. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. Circ Res 2000; 86: E36-41. (Pubitemid 30816014)
63. Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A, Kelly S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001; 104: 1119-1123 (Pubitemid 32830394)
64. Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hubschle T, et al. Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 2008; 325: 370-379 (Pubitemid 351574784)
65. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Longterm vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003; 92: 88-95.
66. d'Uscio LV, Katusic ZS. Increased vascular biosynthesis of tetrahydrobiopterin in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol 2006; 290: H2466-71.
67. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 2001; 281: H981-6.
68. Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, Kubler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000; 102: 2172-2179 (Pubitemid 30808002)
69. Antoniades C, Shirodaria C, Crabtree M, Rinze R, Alp N, Cunnington C, et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007; 116: 2851-2859 (Pubitemid 350291226)
70. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2005; 102: 9056-9061 (Pubitemid 40881077)
71. Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 2007; 113: 47-63. (Pubitemid 47066025)
72. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Yim JJ, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 1990; 265: 3189-3192 (Pubitemid 20087300)
73. Geller DA, Di Silvio M, Billiar TR, Hatakeyama K. GTP cyclohydrolase I is coinduced in hepatocytes stimulated to produce nitric oxide. Biochem Biophys Res Commun 2000; 276: 633-641 (Pubitemid 30750964)
74. Katusic ZS, Stelter A, Milstien S. Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 27-32. (Pubitemid 28047595)
75. Hattori Y, Nakanishi N, Kasai K, Shimoda SI. GTP cyclohydrolase I mRNA induction and tetrahydrobiopterin synthesis in human endothelial cells. Biochim Biophys Acta 1997; 1358: 61-66 (Pubitemid 27365975)
76. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Schmidt K, et al. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem 1993; 268: 1842-1846 (Pubitemid 23033583)
77. Dulak J, Polus M, Guevara I, Polus A, Hartwich J, Dembinska- Kiec A. Regulation of inducible nitric oxide synthase (iNOS) and GTP cyclohydrolase I (GTP-CH I) gene expression by ox-LDL in rat vascular smooth muscle cells. J Physiol Pharmacol 1997; 48: 689-697 (Pubitemid 28055596)
78. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A-11A.
79. Schnabel R, Blankenberg S. Oxidative stress in cardiovascular disease: successful translation from bench to bedside? Circulation 2007; 116: 1338-1340
80. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008; 5: 338-349 (Pubitemid 351761708)
81. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313. (Pubitemid 46209993)
82. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 2005; 65: 16-27. (Pubitemid 40038475)
83. Griendling KK. Novel NAD(P)H oxidases in the cardiovascular system. Heart 2004; 90: 491-493
84. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429-1435 (Pubitemid 34263273)
85. Hathaway CA, Heistad DD, Piegors DJ, Miller FJ, Jr. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 2002; 90: 277-283
86. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, et al. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 1999; 100: 1494-1498 (Pubitemid 29461459)
87. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2002; 22: 1838-1844.
88. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-2033 (Pubitemid 29183901)
89. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006; 48: 677-684 (Pubitemid 44843872)
90. Xu H, Goettsch C, Xia N, Horke S, Morawietz H, Forstermann U, et al. Differential roles of PKCalpha and PKCepsilon in controlling the gene expression of Nox4 in human endothelial cells. Free Radic Biol Med 2008; 44: 1656-1667
91. Herman AG, Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J 2005; 26: 1945-1955 (Pubitemid 41435726)
92. Ishikawa K, Kanamasa K, Ogawa I, Takenaka T, Naito T, Kamata N, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 1996; 60: 779-788 (Pubitemid 26389514)
93. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C. Longterm nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 1999; 138: 577-585 (Pubitemid 29428783)
94. Hink U, Daiber A, Kayhan N, Trischler J, Kraatz C, Oelze M, et al. Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels. J Am Coll Cardiol 2007; 50: 2226-2232 (Pubitemid 350166814)
95. Daiber A, Wenzel P, Oelze M, Munzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 2008; 97: 12-20.
96. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005; 97: 618-628
97. Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, Parker JD. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol 2001; 38: 854-859 (Pubitemid 32835764)
98. Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, Sydow K, et al. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol 2004; 66: 1372-1382 (Pubitemid 39564764)
99. Wenzel P, Oelze M, Coldewey M, Hortmann M, Seeling A, Hink U, et al. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol 2007; 27: 1729-1735 (Pubitemid 47207167)
100. Mollnau H, Wenzel P, Oelze M, Treiber N, Pautz A, Schulz E, et al. Mitochondrial oxidative stress and nitrate tolerance - comparison of nitroglycerin and pentaerithrityl tetranitrate in Mn- SOD+/- mice. BMC Cardiovasc Disord 2006; 6: 44. (Pubitemid 44803699)
101. Dragoni S, Gori T, Lisi M, Di Stolfo G, Pautz A, Kleinert H, et al. Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol 2007; 27: 1955-1959 (Pubitemid 47312304)
102. Hacker A, Muller S, Meyer W, Kojda G. The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br J Pharmacol 2001; 132: 1707-1714 (Pubitemid 32397962)
103. Kojda G, Stein D, Kottenberg E, Schnaith EM, Noack E. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995; 25: 763-773
104. Dikalov S, Fink B, Skatchkov M, Bassenge E. Comparison of glyceryl trinitrate-induced with pentaerythrityl tetranitrate-induced in vivo formation of superoxide radicals: effect of vitamin C. Free Radic Biol Med 1999; 27: 170-176
105. Muller S, Konig I, Meyer W, Kojda G. Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate. J Am Coll Cardiol 2004; 44: 624-631 (Pubitemid 39078190)
106. Muller S, Laber U, Mullenheim J, Meyer W, Kojda G. Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance. J Am Coll Cardiol 2003; 41: 1994-2000. (Pubitemid 36677121)
107. Thum T, Fraccarollo D, Thum S, Schultheiss M, Daiber A, Wenzel P, et al. Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol 2007; 27: 748-754 (Pubitemid 46606702)
108. Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 2006; 26: 2439-2444
109. Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998; 101: 1530-1537
110. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 1997; 29: 8-15. (Pubitemid 27045168)
111. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000; 87: 566-573 (Pubitemid 30745351)
112. Setoguchi S, Mohri M, Shimokawa H, Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol 2001; 38: 493-498 (Pubitemid 32721779)
113. Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, Kasai K. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 865-870 (Pubitemid 46606718)
114. Bagi Z, Koller A. Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type I diabetes is restored by sepiapterin. J Vasc Res 2003; 40: 47-57. (Pubitemid 36351195)
115. Tarpey MM. Sepiapterin treatment in atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 1519-1521
116. Pannirselvam M, Simon V, Verma S, Anderson T, Triggle CR. Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br J Pharmacol 2003; 140: 701-706 (Pubitemid 37386434)
117. Wang S, Xu J, Song P, Wu Y, Zhang J, Chul Choi H, et al. Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension 2008; 52: 484-490
118. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-1550
119. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 1996; 16: 44-50.
120. Aji W, Ravalli S, Szabolcs M, Jiang XC, Sciacca RR, Michler RE, et al. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 1997; 95: 430-437 (Pubitemid 27056211)
121. Blum A, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G, et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000; 101: 2160-2164 (Pubitemid 30253044)
122. Walker HA, McGing E, Fisher I, Boger RH, Bode-Boger SM, Jackson G, et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001; 38: 499-505. (Pubitemid 32721780)
123. Simonet S, Rupin A, Badier-Commander C, Coumailleau S, Behr- Roussel D, Verbeuren TJ. Evidence for superoxide anion generation in aortas of cholesterol-fed rabbits treated with Larginine. Eur J Pharmacol 2004; 492: 211-216 (Pubitemid 38721374)
124. Boger RH. The pharmacodynamics of L-arginine. J Nutr 2007; 137: 1650S-5S.
125. Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-10484 (Pubitemid 21915859)
126. Closs EI, Scheld JS, Sharafi M, Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol 2000; 57: 68-74. (Pubitemid 30033261)
127. Simon A, Plies L, Habermeier A, Martine U, Reining M, Closs EI. Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells. Circ Res 2003; 93: 813-820 (Pubitemid 37363055)
128. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109: 1813-1818
129. Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, Nyhan D, et al. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 2006; 99: 951-960 (Pubitemid 44657798)
130. Lim HK, Lim HK, Ryoo S, Benjo A, Shuleri K, Miriel V, et al. Mitochondrial arginase II constrains endothelial NOS-3 activity. Am J Physiol Heart Circ Physiol 2007; 293: H3317-24. (Pubitemid 350230871)
131. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008; 102: 923-932 (Pubitemid 351591553)
132. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 2005; 10 (Suppl 1): S49-57.
133. Moens AL, Champion HC, Claeys MJ, Tavazzi B, Kaminski PM, Wolin MS, et al. High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 2008; 117: 1810-1819
134. Tian R, Ingwall JS. How does folic acid cure heart attacks? Circulation 2008; 117: 1772-1774
135. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998; 97: 237-241
136. van Etten RW, de Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ. Impaired NO-dependent vasodilation in patients with Type II (non-insulin- dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 2002; 45: 1004-1010
137. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34: 2002-2006 (Pubitemid 30002657)
138. Carnicer R, Navarro MA, Arbones-Mainar JM, Acin S, Guzman MA, Surra JC, et al. Folic acid supplementation delays atherosclerotic lesion development in apoE-deficient mice. Life Sci 2007; 80: 638-643 (Pubitemid 46084932)
139. Moat SJ, Lang D, McDowell IF, Clarke ZL, Madhavan AK, Lewis MJ, et al. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem 2004; 15: 64-79. (Pubitemid 38224347)
140. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-1134 (Pubitemid 30396037)
141. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193-1201 (Pubitemid 44386484)
142. Shirodaria C, Antoniades C, Lee J, Jackson CE, Robson MD, Francis JM, et al. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation 2007; 115: 2262-2270 (Pubitemid 46685894)
143. Moens AL, Vrints CJ, Claeys MJ, Timmermans JP, Champion HC, Kass DA. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am J Physiol Heart Circ Physiol 2008; 294: H1971-7.
144. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577
145. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-1588
146. Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006; 354: 1629-1632
147. Cai S, Alp NJ, McDonald D, Smith I, Kay J, Canevari L, et al. GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res 2002; 55: 838-849 (Pubitemid 34899563)
148. Zheng JS, Yang XQ, Lookingland KJ, Fink GD, Hesslinger C, Kapatos G, et al. Gene transfer of human guanosine 5′-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation 2003; 108: 1238-1245 (Pubitemid 37099994)
149. Takaya T, Hirata K, Yamashita T, Shinohara M, Sasaki N, Inoue N, et al. A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol 2007; 27: 1632-1637 (Pubitemid 46986120)
150. Huang A, Zhang YY, Chen K, Hatakeyama K, Keaney JF, Jr. Cytokine-stimulated GTP cyclohydrolase I expression in endothelial cells requires coordinated activation of nuclear factor-kappaB and Stat1/Stat3. Circ Res 2005; 96: 164-171
151. Schoedon G, Schneemann M, Blau N, Edgell CJ, Schaffner A. Modulation of human endothelial cell tetrahydrobiopterin synthesis by activating and deactivating cytokines: new perspectives on endothelium-derived relaxing factor. Biochem Biophys Res Commun 1993; 196: 1343-1348 (Pubitemid 23347597)
152. Ishii M, Shimizu S, Nagai T, Shiota K, Kiuchi Y, Yamamoto T. Stimulation of tetrahydrobiopterin synthesis induced by insulin: possible involvement of phosphatidylinositol 3-kinase. Int J Biochem Cell Biol 2001; 33: 65-73. (Pubitemid 32146468)
153. Shimizu S, Hiroi T, Ishii M, Hagiwara T, Wajima T, Miyazaki A, et al. Hydrogen peroxide stimulates tetrahydrobiopterin synthesis through activation of the Jak2 tyrosine kinase pathway in vascular endothelial cells. Int J Biochem Cell Biol 2008; 40: 755-765 (Pubitemid 351288596)
154. Shimizu S, Shiota K, Yamamoto S, Miyasaka Y, Ishii M, Watabe T, et al. Hydrogen peroxide stimulates tetrahydrobiopterin synthesis through the induction of GTP-cyclohydrolase I and increases nitric oxide synthase activity in vascular endothelial cells. Free Radic Biol Med 2003; 34: 1343-1352 (Pubitemid 36513975)
155. Miyazaki-Akita A, Hayashi T, Ding QF, Shiraishi H, Nomura T, Hattori Y, et al. 17beta-estradiol antagonizes the down-regulation of endothelial nitric-oxide synthase and GTP cyclohydrolase I by high glucose: relevance to postmenopausal diabetic cardiovascular disease. J Pharmacol Exp Ther 2007; 320: 591-598 (Pubitemid 46147938)
156. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 176-182 (Pubitemid 36231925)
157. Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, Xu J, et al. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 2008; 198: 65-76.
158. Satoh M, Fujimoto S, Arakawa S, Yada T, Namikoshi T, Haruna Y, et al. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 3806-3813
159. Lam CF, Peterson TE, Richardson DM, Croatt AJ, d'Uscio LV, Nath KA, et al. Increased blood flow causes coordinated upregulation of arterial eNOS and biosynthesis of tetrahydrobiopterin. Am J Physiol Heart Circ Physiol 2006; 290: H786-93.
160. Widder JD, Chen W, Li L, Dikalov S, Thony B, Hatakeyama K, et al. Regulation of tetrahydrobiopterin biosynthesis by shear stress. Circ Res 2007; 101: 830-838 (Pubitemid 350287198)
161. De Bono JP, Channon KM. Endothelial cell tetrahydrobiopterin: going with the flow. Circ Res 2007; 101: 752-754
162. d'Uscio LV, Katusic ZS. Erythropoietin increases endothelial biosynthesis of tetrahydrobiopterin by activation of protein kinase B alpha/Akt1. Hypertension 2008; 52: 93-99
163. Li H, Forstermann U. Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitric-oxide synthase gene. Mol Pharmacol 2000; 57: 427-435 (Pubitemid 30140871)
164. Li H, Oehrlein SA, Wallerath T, Ihrig-Biedert I, Wohlfart P, Ulshofer T, et al. Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene. Mol Pharmacol 1998; 53: 630-637 (Pubitemid 28196484)
165. Li H, Hergert SM, Schafer SC, Brausch I, Yao Y, Huang Q, et al. Midostaurin upregulates eNOS gene expression and preserves eNOS function in the microcirculation of the mouse. Nitric Oxide 2005; 12: 231-236 (Pubitemid 40732392)
166. Steinkamp-Fenske K, Bollinger L, Voller N, Xu H, Yao Y, Bauer R, et al. Ursolic acid from the Chinese herb danshen (Salvia miltiorrhiza L.) upregulates eNOS and downregulates Nox4 expression in human endothelial cells. Atherosclerosis 2007; 195: e104-11.
167. Steinkamp-Fenske K, Bollinger L, Xu H, Yao Y, Horke S, Forstermann U, et al. Reciprocal regulation of endothelial nitric-oxide synthase and NADPH oxidase by betulinic acid in human endothelial cells. J Pharmacol Exp Ther 2007; 322: 836-842
168. Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, Urbich C, et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 2006; 103: 14537-14541 (Pubitemid 44484785)
169. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008; 118: 818-827
170. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
171. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211-216 (Pubitemid 28337611)
172. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-1939 (Pubitemid 39331904)
173. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135 (Pubitemid 28152885)
174. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-118 (Pubitemid 32050445)
175. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-69 (Pubitemid 30048347)
176. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305 (Pubitemid 34127043)
177. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565
178. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007; 28: 664-672
179. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008; 51: 734-741 (Pubitemid 351301528)
180. Bauersachs J, Fraccarollo D. More NO - no more ROS: combined selective mineralocorticoid receptor blockade and angiotensin-converting enzyme inhibition for vascular protection. Hypertension 2008; 51: 624-625 (Pubitemid 351301511)
181. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005; 46: 1135-1139 (Pubitemid 41533016)
182. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52: 563-572
183. Verma S, Gupta MK. Aliskiren improves nitric oxide bioavailability and limits atherosclerosis. Hypertension 2008; 52: 467-469
184. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008; 51: 1306-1311 (Pubitemid 351555942)
185. Aversa A, Caprio M, Rosano GM, Spera G. Endothelial effects of drugs designed to treat erectile dysfunction. Curr Pharm Des 2008; 14(35): 3768-3778
186. Chung HT, Pae HO, Cha YN. Role of heme oxygenase-1 in vascular disease. Curr Pharm Des 2008; 14(5): 422-428
187. Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des 2008; 14(25): 2613-2618